These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22484368)

  • 21. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual insurance: health insurers try to tap potential market growth.
    November EA; Cohen GR; Ginsburg PB; Quinn BC
    Res Brief; 2009 Nov; (14):1-8. PubMed ID: 19899193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uninsured status and out-of-pocket costs at midlife.
    Johnson RW; Crystal S
    Health Serv Res; 2000 Dec; 35(5 Pt 1):911-32. PubMed ID: 11130804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 29. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective.
    Emanuele E
    South Med J; 2011 Oct; 104(10):715-6. PubMed ID: 21941163
    [No Abstract]   [Full Text] [Related]  

  • 31. Generic substitution: micro evidence from register data in Norway.
    Dalen DM; Furu K; Locatelli M; Strøm S
    Eur J Health Econ; 2011 Feb; 12(1):49-59. PubMed ID: 20213182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
    Mahlich JC; Stadler I
    Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of generic drug entry on cost-effectiveness analysis.
    Shih YC; Han S; Cantor SB
    Med Decis Making; 2005; 25(1):71-80. PubMed ID: 15673583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MDA's prescription coverage and generic drugs.
    Stafford E
    J Mich Dent Assoc; 2010 May; 92(5):18. PubMed ID: 20536070
    [No Abstract]   [Full Text] [Related]  

  • 35. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit.
    Rodin HA; Heaton AH; Wilson AR; Garrett NA; Plocher DW
    Am J Manag Care; 2009 Dec; 15(12):881-8. PubMed ID: 20001169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents.
    Ferrand Y; Kelton CM; Guo JJ; Levy MS; Yu Y
    Res Social Adm Pharm; 2011 Mar; 7(1):64-80. PubMed ID: 21397882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.
    Romley JA; Sanchez Y; Penrod JR; Goldman DP
    Health Aff (Millwood); 2012 Apr; 31(4):683-90. PubMed ID: 22492884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"].
    Schmidt K
    MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398
    [No Abstract]   [Full Text] [Related]  

  • 40. Generic Price Competition For Specialty Drugs: Too Little, Too Late?
    Cole AL; Dusetzina SB
    Health Aff (Millwood); 2018 May; 37(5):738-742. PubMed ID: 29733710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.